The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma

Journal of Hepatology

Volumn 66, Issue 2, 2017, Pages 338-346

  Pinato, David J ^a   Sharma, Rohini ^a   Allara, Elias ^b   Yen, Clarence ^a   Arizumi, Tadaaki ^c   Kubota, Keiichi ^d   Bettinger, Dominik ^e   Jang, Jeong Won ^f   Smirne, Carlo ^g   Kim, Young Woon ^f   Kudo, Masatoshi ^c   Howell, Jessica ^a   Ramaswami, Ramya ^a   Burlone, Michela E ^g   Guerra, Vito ^h   Thimme, Robert ^e   Ishizuka, Mitsuru ^d   Stebbing, Justin ^a   Pirisi, Mario ^g   Carr, Brian I ⁱ  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

^e UNIVERSITY OF FREIBURG   (Germany)

^f The Catholic University of Korea   (South Korea)

^g UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^h NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

ⁱ DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

ALBI; Albumins; Bilirubin; Biomarkers; Carcinoma; Hepatocellular; Liver failure; Prognosis; Retrospective studies

Indexed keywords

BIOLOGICAL MARKER; SORAFENIB; BILIRUBIN; SERUM ALBUMIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASIA; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CHEMOEMBOLIZATION; EUROPE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RETROSPECTIVE STUDY; UNITED STATES; EPIDEMIOLOGY; LIVER; LIVER TUMOR; MIDDLE AGED; MORTALITY; ORGAN DYSFUNCTION SCORE; PATHOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS;

ADULT; AGED; BILIRUBIN; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; EUROPE; FEMALE; HUMANS; LIVER; LIVER FAILURE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGAN DYSFUNCTION SCORES; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN; SURVIVAL ANALYSIS;

EID: 85006152872     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.09.008     Document Type: Article

References (34)

1. [1] Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics, 2010. CA Cancer J Clin 60 (2010), 277–300.
2. [2] Schutte, K., Bornschein, J., Malfertheiner, P., Hepatocellular carcinoma–epidemiological trends and risk factors. Dig Dis 27 (2009), 80–92.
3. [3] Llovet, J.M., Bruix, J., Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 (2008), S20–S37.
4. [4] Durand, F., Valla, D., Assessment of prognosis of cirrhosis. Semin Liver Dis 28 (2008), 110–122.
5. [5] Cholongitas, E., Papatheodoridis, G.V., Vangeli, M., Terreni, N., Patch, D., Burroughs, A.K., Systematic review: The model for end-stage liver disease–should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?. Aliment Pharmacol Ther 22 (2005), 1079–1089.
6. [6] Procopet, B., Tantau, M., Bureau, C., Are there any alternative methods to hepatic venous pressure gradient in portal hypertension assessment?. J Gastrointestin Liver Dis 22 (2013), 73–78.
7. [7] Cucchetti, A., Cescon, M., Golfieri, R., Piscaglia, F., Renzulli, M., Neri, F., et al. Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. J Hepatol 64 (2016), 79–86.
8. [8] Wiesner, R., Edwards, E., Freeman, R., Harper, A., Kim, R., Kamath, P., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124 (2003), 91–96.
9. [9] Cholongitas, E., Marelli, L., Shusang, V., Senzolo, M., Rolles, K., Patch, D., et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 12 (2006), 1049–1061.
10. [10] Lurie, Y., Webb, M., Cytter-Kuint, R., Shteingart, S., Lederkremer, G.Z., Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol 21 (2015), 11567–11583.
11. [11] Singh, S., Fujii, L.L., Murad, M.H., Wang, Z., Asrani, S.K., Ehman, R.L., et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 11 (2013), 1573–1584 e1571–e1572; quiz e1588–e1579.
12. [12] Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33 (2015), 550–558.
13. [13] Dufour, J.F., Bargellini, I., De Maria, N., De Simone, P., Goulis, I., Marinho, R.T., Intermediate hepatocellular carcinoma: current treatments and future perspectives. Ann Oncol 24 (2013), ii24–ii29.
14. [14] European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
15. [15] Llovet, J.M., Bru, C., Bruix, J., Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19 (1999), 329–338.
16. [16] Pinato, D.J., Stebbing, J., Ishizuka, M., Khan, S.A., Wasan, H.S., North, B.V., et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol 57 (2012), 1013–1020.
17. [17] Carr, B.I., Kondragunta, V., Buch, S.C., Branch, R.A., Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116 (2010), 1305–1314.
18. [18] Pinato, D.J., Arizumi, T., Allara, E., Jang, J.W., Smirne, C., Kim, Y.W., et al. Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification. Clin Gastroenterol Hepatol, 13, 2015, e1202.
19. [19] Lencioni, R., Llovet, J.M., Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30 (2010), 52–60.
20. [20] Team RC. R: A language and environment for statistical computing. 2014, R Foundation for Statistical Computing, Vienna.
21. [21] Harrell FE. Regression Modeling Strategies. 3.0 ed; 2010.
22. [22] Liu, P.H., Hsu, C.Y., Hsia, C.Y., Lee, Y.H., Su, C.W., Huang, Y.H., et al. Prognosis of hepatocellular carcinoma: assessment of eleven staging systems. J Hepatol 64 (2016), 601–608.
23. [23] de Lope, C.R., Tremosini, S., Forner, A., Reig, M., Bruix, J., Management of HCC. J Hepatol 56 (2012), S75–S87.
24. [24] Sangro, B., Salem, R., Transarterial chemoembolization and radioembolization. Semin Liver Dis 34 (2014), 435–443.
25. [25] Bolondi, L., Burroughs, A., Dufour, J.F., Galle, P.R., Mazzaferro, V., Piscaglia, F., et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 32 (2012), 348–359.
26. [26] Llovet, J.M., Schwartz, M., Mazzaferro, V., Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25 (2005), 181–200.
27. [27] Sacco, R., Antonucci, M., Bresci, G., Corti, A., Giacomelli, L., Mismas, V., et al. Curative therapies for hepatocellular carcinoma: an update and perspectives. Expert Rev Anticancer Ther 16 (2016), 169–175.
28. [28] Hiraoka, A., Kumada, T., Michitaka, K., Toyoda, H., Tada, T., Ueki, H., et al. Usefulness of albumin-bilirubin (ALBI) grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol 31 (2016), 1031–1036.
29. [29] Chan, A.W., Kumada, T., Toyoda, H., Tada, T., Chong, C.C., Mo, F.K., et al. Integration of albumin-bilirubin (ALBI) score into Barcelona clinic liver cancer (BCLC) system for hepatocellular carcinoma. J Gastroenterol Hepatol 31 (2016), 1300–1306.
30. [30] Kadalayil, L., Benini, R., Pallan, L., O'Beirne, J., Marelli, L., Yu, D., et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 24 (2013), 2565–2570.
31. [31] Pinato, D.J., Karamanakos, G., Arizumi, T., Adjogatse, D., Kim, Y.W., Stebbing, J., et al. Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 40 (2014), 1270–1281.
32. [32] Hucke, F., Pinter, M., Graziadei, I., Bota, S., Vogel, W., Muller, C., et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol 61 (2014), 1287–1296.
33. [33] Pressiani, T., Boni, C., Rimassa, L., Labianca, R., Fagiuoli, S., Salvagni, S., et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 24 (2013), 406–411.
34. [34] Lg, D.A.F., Barroso-Sousa, R., Bento, A.D., Blanco, B.P., Valente, G.L., Pfiffer, T.E., et al. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Mol Clin Oncol 3 (2015), 793–796.